Clinical trials: Recurrent Ovarian Carcinoma
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00070096
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Neoplasms, Endometrial Neoplasms
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer
- Trial name
- DOVE (NCT06023862)
- Testing
- Dostarlimab, Bevacizumab, Doxorubicin
- Where
- 27 sites in Australia, Hong Kong and 5 more
- Volunteers
- 198 people
- Sponsor
- Yonsei University
Ovarian Cancer, Triple Negative Breast Cancer
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Fluzoparib is an oral potent, selective poly-ADP ribose polymerase-1 (PARP-1) and PARP-2 inhibitor; Apatinib is an oral selective vascular endothelial growth factor receptor (VEGFR) inhibitor.
- Trial name
- NCT03075462
- Testing
- Fluzoparib, Apatinib
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ovarian Cancer, Fallopian Tube Cancer
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
This study is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in PFS (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in combination with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00479817
- Testing
- AMG 386, Paclitaxel
- Volunteers
- 161 people
- Sponsor
- Amgen
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at…
- Trial name
- SOLO3 (NCT02282020)
- Testing
- OLAPARIB, Single agent chemotherapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Fallopian Tube Cancer, Ovarian Cancer
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients with…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00019461
- Testing
- carboxyamidotriazole, chemotherapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Testicular Germ Cell Tumor
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002559
- Testing
- filgrastim, cisplatin, ifosfamide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer
Based on these pre-clinical data, which were generated by our group, the investigators propose to test in a phase I/II clinical trial the following hypothesis: demethylation induced by decitabine results in re-sensitization to…
- Trial name
- NCT00477386
- Testing
- decitabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Indiana University
Fallopian Tube Cancer, Ovarian Cancer
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00014690
- Testing
- plevitrexed, topotecan hydrochloride
- Where
- United States
- Sponsor
- AstraZeneca
Fallopian Tube Cancer, Ovarian Cancer
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00748527
- Testing
- carboplatin, decitabine
- Where
- 11 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- Cancer Research UK
HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
This study will evaluate the recommended Phase 2 combination dose (RP2D) of eribulin with durvalumab.
- Trial name
- NCT03430518
- Testing
- Durvalumab, Eribulin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Amy Tiersten
Ovarian Cancer
Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
PARP inhibitors, such as olaparib, significantly improve progression free survival (PFS) in participants with recurrent, platinum-sensitive high-grade serous/endometrioid ovarian cancer (HGS/EOC), who harbour a germline mutation…
- Trial name
- MOLTO (NCT02855697)
- Testing
- Olaparib, Cediranib, Platinum-based Chemotherapy
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- The Christie NHS Foundation Trust
Fallopian Tube Cancer, Ovarian Cancer
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00617773
- Testing
- hu3S193
- Where
- 8 sites in Brazil
- Volunteers
- 31 people
- Sponsor
- Recepta Biopharma
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill the tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have ovarian…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00006041
- Testing
- MUC1-KLH conjugate vaccine, MUC1-KLH vaccine/QS21, QS21
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Peritoneal Cancer, Ovarian Cancer
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT02873962
- Testing
- Bevacizumab, Nivolumab, Rucaparib
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer
Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer
The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend Phase 2 Dose (RP2D) of KM1 in the treatment…
- Trial name
- K19017-004 (NCT05684731)
- Testing
- KM1, Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Ovarian Cancer Recurrent
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial…
- Trial name
- NCT03657966
- Testing
- DCVAC/OvCa, Standard of Care Chemotherapy
- Where
- 8 sites in Czechia
- Volunteers
- 33 people
- Sponsor
- SOTIO a.s.
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
This phase I/II trial studies the side effects and best dose of olaparib when give together with durvalumab and tremelimumab and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal…
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT02953457
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Roswell Park Cancer Institute
High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
This phase I/II trial studies how well birinapant and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back.
- Conditions
- High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT02756130
- Testing
- Birinapant, Carboplatin, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center